249 related articles for article (PubMed ID: 26945902)
21. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma.
Kong SK; Kim BS; Lim H; Kim HJ; Kim YS
Lab Invest; 2022 Apr; 102(4):352-362. PubMed ID: 34789838
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
24. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S
Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
27. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
28. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.
Moch H; Lukamowicz-Rajska M
Cancer Discov; 2014 Jan; 4(1):22-4. PubMed ID: 24402943
[TBL] [Abstract][Full Text] [Related]
29. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
[TBL] [Abstract][Full Text] [Related]
30. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
32. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
33. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
34. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
35. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
36. Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.
Swiatek M; Jancewicz I; Kluebsoongnoen J; Zub R; Maassen A; Kubala S; Udomkit A; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1220-1232. PubMed ID: 32250548
[TBL] [Abstract][Full Text] [Related]
37. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
38. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients.
Kroeze SG; Vermaat JS; van Brussel A; van Melick HH; Voest EE; Jonges TG; van Diest PJ; Hinrichs J; Bosch JL; Jans JJ
Eur J Cancer; 2010 Dec; 46(18):3375-82. PubMed ID: 20709525
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
40. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
